Definitive Contract 75D30122C15048
Award Date
9/30/22
Potential Completion Date
9/29/23
Potential Value
$2.2M
Federal Agency
CDC Pittsburgh
Awardee
Helix Opco LLC
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Mateo, CA 94401, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
273
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $5,000,000.00 firm fixed price contract awarded by the Centers for Disease Control and Prevention (CDC) to Helix Opco LLC, a for-profit limited liability company based in San Mateo, California. The contract was awarded on September 30, 2022 under the CDC's "FY22 BAA - APPLIED RESEARCH TO ADDRESS EMERGING PUBLIC HEALTH PRIORITIES" solicitation, with a period of performance ending on September 29, 2023. The contract does not have a set-aside designation. Helix Opco has...
This is a $81,891,810.00 definitive, firm fixed price contract awarded by the Centers for Disease Control and Prevention (CDC) to Helix Opco LLC, a for-profit limited liability company located in San Mateo, California. The contract is for "Genomic Sequencing for COVID-19" and has a period of performance through April 28, 2025. No set-aside designation was used. Based on Helix Opco's past federal contracting history, the company has provided genomic sequencing services for COVID-19...
Helix Opco, LLC was awarded a $10.88 million firm fixed price definitive contract by the Centers for Disease Control and Prevention (CDC) on September 17, 2021 to provide genomic sequencing services. The contract has a period of performance through May 14, 2022 and was issued without a set-aside designation. As a for-profit limited liability company located in San Mateo, California, Helix Opco will deliver the sequencing services from its place of performance in the same city. No major...
This is a firm fixed price contract award to Illumina, Inc., a manufacturer of genetic and genomic analysis instruments and reagents, by the Centers for Disease Control and Prevention (CDC) for laboratory equipment. The contract has a ceiling value of $232,307.62 and a completion date of October 24, 2016. It is a Blanket Purchase Agreement (BPA) call, which suggests it is part of a larger contracting vehicle. Illumina has a history of providing sequencing systems, reagents, and bioinformatics...
This contract award to The Johns Hopkins University (JHU) for $1,358,321 is for the provision of FY 21 BAA TOPIC 8 services to the Centers for Disease Control and Prevention (CDC). The contract is a definitive, firm-fixed-price agreement with a completion date of November 16, 2023. It is not associated with any set-aside designation. The main subcontractors are Oxford Nanopore Technologies PLC and Oxford Nanopore Technologies Inc., who are providing DNA/RNA sequencing equipment, consumables, and...
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the provision of Genomic Sequencing Kits with a ceiling value of $170,641.14 and a performance period ending on August 28, 2024. The contract does not utilize a set-aside designation. Illumina is the prime contractor and has been awarded multiple federal contracts...
The Centers for Disease Control and Prevention awarded a $3.975 million firm fixed price definitive contract to Illumina, Inc. of San Diego, California. The contract is for SARS-COV-2 SPHERES Baseline Genomic Sequencing to support the Department of Health and Human Services and CDC's efforts responding to the Coronavirus Disease 2019 (COVID-19) pandemic. Under this contract, Illumina will provide genomic sequencing and data analysis services to establish a baseline of SARS-CoV-2 virus genomes...
The Centers for Disease Control and Prevention awarded a $600,000 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract calls for SARS-COV-2 SPHERES baseline genomic sequencing in support of the CDC's coronavirus COVID-19 programs. Performance will take place in San Diego through March 2021. As the leading public health agency in the U.S., the CDC routinely sequences virus genomes to track disease spread and evolution, providing genomic surveillance critical...
This is a firm fixed price purchase order service agreement awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh office, a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing systems and reagents. The contract has a ceiling value of $236,726.60 and a period of performance through August 31, 2025. It does not have a set-aside designation. The contract provides for Illumina to furnish genomic sequencing goods and services, likely building on...
This federal contract award to Illumina, Inc. is a Blanket Purchase Agreement (BPA) call from the Centers for Disease Control and Prevention (CDC), which is part of the U.S. Department of Health and Human Services (HHS). The contract has a potential value of $125,330.32 and is for a firm fixed price. Illumina, a manufacturer of sequencing and array-based solutions, will provide goods and services to support genomic sequencing and analysis for research and diagnostics purposes. This includes...